Cover Image

Temporary oral anticoagulation after MitraClip: a strategy to lower the incidence of post-procedural stroke?

Incidence of stroke within 30 days after percutaneous mitral valve repair using the MitraClip varies from 0.7% and 2.6% between registries. Standard medical treatment after the MitraClip procedure, in the absence of risk factors requiring antithrombotic therapy such as atrial fibrillation, is dual a...

Full description

Saved in:
Bibliographic Details
Main Authors: Geis, Nicolas (Author) , Raake, Philip (Author) , Kiriakou, Christina (Author) , Mereles, Derliz (Author) , Frankenstein, Lutz (Author) , Abu Sharar, Haitham (Author) , Chorianopoulos, Emmanuel (Author) , Katus, Hugo (Author) , Bekeredjian, Raffi (Author) , Pleger, Sven Torsten (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Acta cardiologica
Year: 2019, Volume: 75, Issue: 1, Pages: 61-67
ISSN:1784-973X
DOI:10.1080/00015385.2018.1550886
Online Access:Resolving-System, Volltext: https://doi.org/10.1080/00015385.2018.1550886
Verlag: https://www.tandfonline.com/doi/full/10.1080/00015385.2018.1550886
Get full text
Author Notes:Nicolas Geis, Philip Raake, Christina Kiriakou, Derliz Mereles, Lutz Frankenstein, Haitham Abu-Sharar, Emmanuel Chorianopoulos, Hugo A. Katus, Raffi Bekeredjian & Sven T. Pleger
Description
Summary:Incidence of stroke within 30 days after percutaneous mitral valve repair using the MitraClip varies from 0.7% and 2.6% between registries. Standard medical treatment after the MitraClip procedure, in the absence of risk factors requiring antithrombotic therapy such as atrial fibrillation, is dual antiplatelet therapy using aspirin and clopidogrel. ESC/EACTS and ACC/AHA surgical guidelines show a Class IIa indication for temporary antithrombotic therapy after mitral valve repair/bioprosthetic valve replacement within the first three months even in patients with no additional risk factors.
Item Description:Published online: 16 Jan 2019
Gesehen am 27.02.2020
Physical Description:Online Resource
ISSN:1784-973X
DOI:10.1080/00015385.2018.1550886

Similar Items